The primary outcome , the placebo-corrected mean ratio of the UACR at day 90 relative to baseline , was reduced in the finerenone 7.5 - , 10 - , 15 - , and 20-mg/d groups ( for 7.5 mg/d , 0.79 [ 90 % CI , 0.68-0 .91 ; P = .004 ] ; for 10 mg/d , 0.76 [ 90 % CI , 0.65-0 .88 ; P = .001 ] ; for 15 mg/d , 0.67 [ 90 % CI , 0.58-0 .77 ; P < .001 ] ; for 20 mg/d , 0.62 [ 90 % CI , 0.54-0 .72 ; P < .001 ] ) .